Moreover, we observed that HER2 positivity either alone, or alongside with HR positivity, was associated with an increased risk of death in PTEN-L breast cancers (p < 0.0001 and p = 0.002, respectively), as shown in Fig. 4. This evidence concerns the gene ERBB2 and breast carcinoma.